BACKGROUND: Indications for a heart‒liver transplantation (HLT) for Fontan recipients are not well defined. We compared listing characteristics, post-operative complications, and post-transplant outcomes of Fontan recipients who underwent HLT with those of patients who underwent heart-only transplantation (HT). We hypothesized that patients who underwent HLT have increased post-operative complications but superior survival outcomes compared with patients who underwent HT. METHODS: We performed a retrospective review of Fontan recipients who underwent HLT or HT at a single institution. Characteristics at the time of listing, including the extent of liver disease determined by laboratory, imaging, and biopsy data, were compared. Post-operative complications were assessed, and the Kaplan‒Meier survival method was used to compare post-transplant survival. Univariate regression analyses were performed to identify the risk factors for increased mortality and morbidity among patients who underwent HT. RESULTS: A total of 47 patients (9 for HLT, 38 for HT) were included. Patients who underwent HLT were older, were more likely to be on dual inotrope therapy, and had evidence of worse liver disease. Whereas ischemic time was longer for the group who underwent HLT, post-operative complications were similar. Over a median post-transplant follow-up of 17 (interquartile range: 5-52) months, overall mortality for the cohort was 17%; only 1 patient who underwent HLT died (11%) vs 7 patients who underwent HT (18%) (p = 0.64). Among patients who underwent HT, cirrhosis on pre-transplant imaging was associated with worse outcomes. CONCLUSIONS: Despite greater inotrope need and more severe liver disease at the time of listing, Fontan recipients undergoing HLT have post-transplant outcomes comparable with those of patients undergoing HT. HLT may offer a survival benefit for Fontan recipients with liver disease.
BACKGROUND: Indications for a heart‒liver transplantation (HLT) for Fontan recipients are not well defined. We compared listing characteristics, post-operative complications, and post-transplant outcomes of Fontan recipients who underwent HLT with those of patients who underwent heart-only transplantation (HT). We hypothesized that patients who underwent HLT have increased post-operative complications but superior survival outcomes compared with patients who underwent HT. METHODS: We performed a retrospective review of Fontan recipients who underwent HLT or HT at a single institution. Characteristics at the time of listing, including the extent of liver disease determined by laboratory, imaging, and biopsy data, were compared. Post-operative complications were assessed, and the Kaplan‒Meier survival method was used to compare post-transplant survival. Univariate regression analyses were performed to identify the risk factors for increased mortality and morbidity among patients who underwent HT. RESULTS: A total of 47 patients (9 for HLT, 38 for HT) were included. Patients who underwent HLT were older, were more likely to be on dual inotrope therapy, and had evidence of worse liver disease. Whereas ischemic time was longer for the group who underwent HLT, post-operative complications were similar. Over a median post-transplant follow-up of 17 (interquartile range: 5-52) months, overall mortality for the cohort was 17%; only 1 patient who underwent HLT died (11%) vs 7 patients who underwent HT (18%) (p = 0.64). Among patients who underwent HT, cirrhosis on pre-transplant imaging was associated with worse outcomes. CONCLUSIONS: Despite greater inotrope need and more severe liver disease at the time of listing, Fontan recipients undergoing HLT have post-transplant outcomes comparable with those of patients undergoing HT. HLT may offer a survival benefit for Fontan recipients with liver disease.
Authors: Matthew C Schwartz; Lisa Sullivan; Meryl S Cohen; Pierre Russo; Anitha S John; Rong Guo; Marta Guttenberg; Elizabeth B Rand Journal: J Thorac Cardiovasc Surg Date: 2011-09-28 Impact factor: 5.209
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Alan S Chou; Andreas Habertheuer; Amanda L Chin; Ibrahim Sultan; Prashanth Vallabhajosyula Journal: Ann Thorac Surg Date: 2019-03-15 Impact factor: 4.330
Authors: Sumeet S Vaikunth; Waldo Concepcion; Tami Daugherty; Michael Fowler; Glen Lutchman; Katsuhide Maeda; David N Rosenthal; Jeffrey Teuteberg; Y Joseph Woo; George K Lui Journal: Clin Transplant Date: 2019-04-11 Impact factor: 2.863
Authors: Kathleen E Simpson; Elizabeth Pruitt; James K Kirklin; David C Naftel; Rakesh K Singh; R Erik Edens; Aliessa P Barnes; Charles E Canter Journal: Ann Thorac Surg Date: 2016-11-15 Impact factor: 4.330
Authors: Eliza W Beal; Khalid Mumtaz; Don Hayes; Bryan A Whitson; Sylvester M Black Journal: Transplant Rev (Orlando) Date: 2016-07-17 Impact factor: 3.943
Authors: Helen S Te; Allen S Anderson; J Michael Millis; Valluvan Jeevanandam; Donald M Jensen Journal: J Heart Lung Transplant Date: 2008-07 Impact factor: 10.247
Authors: Roosevelt Bryant; Raheel Rizwan; Farhan Zafar; Shimul A Shah; Clifford Chin; James S Tweddell; David L Morales Journal: Transplantation Date: 2018-02 Impact factor: 4.939
Authors: George K Lui; Arwa Saidi; Ami B Bhatt; Luke J Burchill; Jason F Deen; Michael G Earing; Michael Gewitz; Jonathan Ginns; Joseph D Kay; Yuli Y Kim; Adrienne H Kovacs; Eric V Krieger; Fred M Wu; Shi-Joon Yoo Journal: Circulation Date: 2017-10-09 Impact factor: 29.690